@article{ATM20324,
author = {Cristiana Lo Nigro and Daniela Vivenza and Nerina Denaro and Laura Lattanzio and Mirella Fortunato and Tim Crook and Marco Carlo Merlano},
title = {DUSP2 methylation is a candidate biomarker of outcome in head and neck cancer},
journal = {Annals of Translational Medicine},
volume = {6},
number = {13},
year = {2018},
keywords = {},
abstract = {Background: Biomarkers predictive of response to chemoradiotherapy (CRT) regimens for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) are urgently required to identify patients in whom this approach is likely to be effective. TP53 mutations and epidermal growth factor (EGFR) overexpression are common markers of disease. Dual-specificity-phosphatase-2 (DUSP2) has an essential role in cell proliferation, cancer and immune responses.
Methods: Aberrant DUSP2 methylation was investigated by pyrosequencing in 5 HNSCC cell lines, 112 LA-HNSCC tumours. EGFR was investigated by immunohistochemistry and TP53 was analysed by sequencing.
Results: We demonstrate methylation-dependent transcriptional silencing of DUSP2 in HNSCC cell lines. In LA-HNSCC patients, aberrant methylation in the DUSP2 CpG island was present in 51/112 cases (45.5%). LA-HNSCC cases with wild-type TP53, overexpression of EGFR and unmethylated DUSP2 had the worst overall survival (P≤0.001).
Conclusions: DUSP2 methylation, when combined with EGFR and TP53, is a candidate biomarker of clinical outcome in LA-HNSCC treated with CRT.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/20324}
}